Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT06956326
Recruiting Phase 2

Illuminating New Paths in the Treatment of Multiple Sclerosis Relapses - Early and Specialized Rehabilitation

NCT06956326 · tracked via the Priya Life Science Denmark tracker
Sponsor
Lars Hvid
Phase
Phase 2
Started
2025-05-01
Last updated
2025-05-04

Condition(s) studied

Multiple Sclerosis

Investigational drug(s) / intervention(s)

Intensive rehabUsual care

Intensive rehab: Frequent moderate-to-high intensity physical therapy, provided by local physiotherapists.

Usual care: Usual care physiotherapy

Study summary

The overall purpose of this project is to develop and test an infrastructure that can ensure early and specialized rehabilitation for individuals with multiple sclerosis (MS) on their path to recovery from a relapse. If this project proves successful, it can therefore help optimize clinical practice and provide a significant contribution to the treatment of relapsing-remitting sclerosis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * admitted to the Danish MS Hospitals for an inpatient rehabilitation stay * confirmed motor relapse (within the past 6 months) by a neurologist, with disability/ functional interference characterized by change in pyramidal, and/or cerebellar functional scores of 2 or higher * completed steroid or other acute relapse treatment, if prescribed * age over 18 years Exclusion Criteria: * more than 6 months since onset of motor relapse * medical conditions or substantial cognitive impairments that hinder participation in the study (e.g. inability to perform or understand the intensive rehabilitation) * pregnancy

Primary outcome measure(s)

  • Expanded Disability Status Scale (EDSS) — Change from Baseline to 52 weeks
    The Expanded Disability Status Scale measures your current level of disability.
  • MS Functional Composite (MSFC) Score — Change from Baseline to 52 weeks
    A standardized tool used to quantify the degree of disability in patients with multiple sclerosis (MS).

Trial sites (2)

FacilityCityRegionStatus
The Danish MS Hospitals Haslev Denmark Recruiting
The Danish MS Hospitals Ry Denmark Recruiting

Other trials for the same condition

Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction Recruiting
Resistance Training and Corticospinal Excitability in Multiple Sclerosis Recruiting
MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect Active, not recruiting
Implementation of an Advanced Telerehabilitation Solution for People With Multiple Sclerosis Starting soon
At Home Use of Stimulation Suits for Managing MS Symptoms Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06956326 on ClinicalTrials.gov ↗ ← All trials in Denmark